Promising Drug Study in Pancreatic Cancer
A new drug called daraxonrasib, which was determined in clinical tests to significantly extend patients' lifespans, has been approved by the US Food and Drug Administration.
Developed by Revolution Medicines and branded as Rasonque, daraxonrasib has drawn attention in the medical world and received early approval by doubling survival time in pancreatic cancer treatment.
Clinical Trial Results
In the late-stage clinical trial involving five hundred patients, the average survival time of patients taking daraxonrasib daily in pill form was recorded as 13.2 months.
In the same study, it was determined that the average survival time for patients receiving conventional chemotherapy remained at 6.6 months.
Mechanism of Action of the Drug
Daraksonrasib targets the mutated KRAS gene, which is found in more than ninety percent of pancreatic tumors and triggers cancer development.
By disabling this gene, the drug helps prevent the spread of cancer and offers a new option in the fight against this challenging disease.
FDA Approval and Process
The US Food and Drug Administration had granted the drug Breakthrough Therapy designation in 2025 to address an unmet medical need.
Angelo de Claro, Director of the FDA Oncology Center of Excellence, announced that the drug received early approval by six months due to delivering unprecedented results.
Side Effect Rates
The most common side effects of the treatment include skin rash, diarrhea, nausea, fatigue, and vomiting.
In the clinical trial, serious side effects were observed in forty-four percent of those using daraxonrasib, while this rate was fifty-seven and a half percent in the chemotherapy group.